ArriVent BioPharma (AVBP) Free Cash Flow (2023 - 2026)
ArriVent BioPharma (AVBP) reported Free Cash Flow of -$41.9 million for Q1 2026, up 38.4% on a YoY basis from -$30.3 million in Q1 2025, and down 36.64% sequentially from -$30.7 million in Q4 2025.
ArriVent BioPharma (AVBP) Free Cash Flow (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Free Cash Flow data on file, last reported at -$41.9 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 38.4% year-over-year to -$41.9 million; the trailing twelve-month figure through Mar 2026 stood at -$134.5 million (down 12.44% YoY), and the FY2025 full-year result was -$160.6 million, down 128.72% from the prior year.
- Free Cash Flow declined to -$41.9 million in Q1 2026, from -$30.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$8.6 million in Q2 2023 to a low of -$68.0 million in Q1 2025.
- A 4-year average of -$25.3 million and a median of -$18.6 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 265.08% in 2025 and soared 38.4% in 2026, its largest moves.
- Tracing AVBP's Free Cash Flow over 4 years: stood at -$14.9 million in 2023, then slipped by 8.31% to -$16.2 million in 2024, then slumped by 89.81% to -$30.7 million in 2025, then plunged by 36.64% to -$41.9 million in 2026.
- Business Quant data shows AVBP's Free Cash Flow at -$41.9 million in Q1 2026, -$30.7 million in Q4 2025, and -$35.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | -41.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.89 Mn |
| Mar 31, 2026 | -41.89 Mn |
| Dec 31, 2025 | -30.66 Mn |
| Dec 31, 2025 | -30.66 Mn |
| Sep 30, 2025 | -35.80 Mn |
| Sep 30, 2025 | -35.80 Mn |
| Jun 30, 2025 | -26.12 Mn |
| Jun 30, 2025 | -26.12 Mn |
| Mar 31, 2025 | -68.01 Mn |
| Mar 31, 2025 | -68.01 Mn |
| Dec 31, 2024 | -16.15 Mn |
| Dec 31, 2024 | -16.15 Mn |
| Sep 30, 2024 | -16.35 Mn |
| Sep 30, 2024 | -16.35 Mn |
| Jun 30, 2024 | -19.09 Mn |
| Jun 30, 2024 | -19.09 Mn |
| Mar 31, 2024 | -18.63 Mn |
| Mar 31, 2024 | -18.63 Mn |
| Dec 31, 2023 | -14.91 Mn |
| Dec 31, 2023 | -14.91 Mn |